[Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa].

Abstract

With the goal to evaluate the long term efficacy and tolerance of pirozadil, 20 patients with hypercholesterolemia (type II a hyperlipoproteinemia) received this drug for 4.5 years. Lipidic parameters and the appearance of subjective manifestations related to the drug were periodically controlled. The triglyceride concentration (34%), total cholesterol (24%) and LDL-cholesterol (47%) decreased after 6 months of treatment with 1.5 to 2 g/day of pirozadil. These changes were more manifest during the second semester of therapy and did not show important oscolations in subsequent controls. Adverse effects, indicating the withdrawal of the drug were not encountered. Three patients had minor and transient epigastralgias. Taken as a whole, these results reinforce the usefulness of pirozadil in treating patients with hypercholesterolemias.

• Authors: C Cuchi de la Cuesta, M T Cuchi Alfaro, C Cuchi Alfaro
• Journal: Revista clinica espanola (Rev Clin Esp) Vol. 184 Issue 1 Pg. 24-6 (Jan 1989) ISSN: 0014-2565 [Print] Spain
• Vernacular Title: Evaluación clínica del pirozadil administrado ininterrumpidamente durante 4.5 años a pacientes con hiperlipoproteinemia tipo IIa.
• PMID: 2704867 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anticholesteremic Agents
• Pyridines
• pirozadil
• Cholesterol

Topics

• Aged
• Anticholesteremic Agents (administration & dosage)
• Cholesterol (blood)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Female
• Humans
• Hyperlipoproteinemia Type II (blood, drug therapy)
• Male
• Middle Aged
• Pyridines (administration & dosage)